Effectiveness of Vitamin C in reducing morbidity in patients with Dengue fever - A double blinded randomized placebo controlled pilot study.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2017/028

Enrollment

Unknown

Registered

2017-08-30

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue fever

Interventions

The study will be carried out in the medical wards of the Teaching Hospital, Karapitiya, Sri Lanka. Patients will be randomized using simple randomization. Those in the treatment arm would receive or

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged 12-70 years. 2. Previously healthy patients coming with dengue fever 3. Within the first 3 days of fever 4. Positive NS1 dengue antigen 5. Platelet count more than 100 000/mm3

Exclusion criteria

Exclusion criteria: 1. Patients under age of 12 years and above 70 years 2. Those who have any evidence of plasma leakage, shock or impeding shock, fluid overload, internal bleeding at that time of recruitment 3. Those who have severe vomiting or inability to take oral fluids 4. Drowsy patients - Drowsiness will be assessed clinically based on appearance followed by glasgow coma scale. 5. Those who have liver failure with clinical or biochemical evidence 6. Those who have AST or ALT more than 100 IU/L on admission 7. Patients with other co-morbidities such as diabetes mellitus, hypertension, ischemic heart disease, bronchial asthma, thyroid disorders etc. 8. Patients who are on other medication (statins, metformin, beta blockers) 9. Patients who are severely dehydrated 10. Patients who get admitted later (more than 3 days after onset of fever) 11. Patients who are extremely obese,- BMI more than 27 kg/m2 12. Patients with known fatty liver disease 13. Patients who have used any alternative medicine eg:- indigenous medicine 14. Patients with diagnosed mental illness 15. Patients with ongoing other infections, malignancy

Design outcomes

Primary

Measure	Time frame
Number of days need to be hospitalised. [Daily during hospital stay] Number of patients going into leaking phase [Daily during hospital stay] Secondary bacterial infection [Daily during hospital stay]	—

Secondary

Measure	Time frame
None [None]	—

Countries

Sri Lanka

Contacts

Public ContactDr. H M M Herath

Senior Lecturer in Clinical Medicine, Consultant Physician

herathtp@gmail.comTel: +94912234803

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026